SAN FRANCISCO, and HERZLIYA, Israel, Aug. 8, 2019 /PRNewswire/ -- 89Bio Ltd. (89bio), a clinical-stage biopharmaceutical company, today announced that the first patients have been screened in its proof of concept Phase 1b/2a clinical trial evaluating its investigational product candidate, BIO89-100, a glycoPE

TORONTO, Aug. 8, 2019 /PRNewswire/ -- DW Healthcare Partners ("DWHP"), a healthcare-focused private equity firm, announced today a majority investment in CEFALY Technology SPRL ("CEFALY"), a leading global manufacturer and marketer of neuro-modulating medical devices for the prevention and treatment of migraines. CEFALY is the first investment in

BIRMINGHAM, Ala., Aug. 8, 2019 /PRNewswire/ -- Encompass Health Corp. (NYSE: EHC) today announced it will participate in the Baird Global Healthcare Conference in New York City and the Wells Fargo Securities Healthcare Conference in Boston. Both conferences will occur Sept. 4-5,

STOCKHOLM, Aug. 8, 2019 /PRNewswire/ -- The data generated from a unique single sequence on the Siemens Healthineers MRI system and SyMRI software provide quantitative MRI, tissue specific parametric maps (R1, T1, R2, T2 and PD), multiple contrast-weighted images and tissue volumes. This supports a faster scan time while providing more information

LEXINGTON, Mass., Aug. 8, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies1 and cancer vaccines, announced today that the FDA has accepted the company's IND filing for AGEN2373, a milestone 

LEXINGTON, Mass., Aug. 8, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies1, and cancer vaccines provided corporate updates and reported financial results for the second quarter of 2019.

Record Revenue of $9.4 Million and Adjusted EBITDA of $5.1 Million LAVAL, QC, Aug. 8, 2019 /PRNewswire/ - Crescita Therapeutics Inc. (TSX: CTX) (OTC US: CRRTF) (Crescita or the Company), a Canadian commercial dermatology company with manufacturing capabilities and a portfolio o

BETHESDA, Md., Aug. 8, 2019 /PRNewswire/ -- The American College of Medical Genetics and Genomics (ACMG) is announcing the establishment of an Evidence-Based Guidelines (EBG) Program, including a staff team dedicated to new evidence-based guideline development in the medical genetics and genomics field.

- Sierra preparing to launch the MOMENTUM Phase 3 myelofibrosis clinical trial expected in Q4 2019 -- Exploring non-dilutive options to support future continued development of DDR portfolio - VANCOUVER, Aug 8, 2019 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on advancing targeted therapeutics

BURLINGTON, ON and BRANTFORD, ON, Aug. 8, 2019 /PRNewswire/ - Rapid Dose Therapeutics Corp. (CSE: DOSE), ("RDT")